We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
- Authors
Holen, Kyle; DiPaola, Robert; Liu, Glenn; Tan, Antoinette R; Wilding, George; Hsu, Karl; Agrawal, Nancy; Chen, Cong; Xue, Lingling; Rosenberg, Elizabeth; Stein, Mark
- Abstract
The kinesin spindle protein (KSP) is essential for separation of spindle poles during mitosis. Its inhibition results in mitotic arrest. This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP.
- Publication
Investigational new drugs, 2012, Vol 30, Issue 3, p1088
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-011-9653-1